Next up is Kirsten Johansen from U of Minnesota on Emerging therapies for CKD-related anemia. She starts with a question. This is a nightmare question and will not be participating. She mocks the audience for answering wrong. #NKFClinicals 
Big list of trials so you can keep the trials straight #NKFClinicals
After showing data that the HIF stabilizers raise the hemoglobin she gets to the MACE data. First up Roxa. (Emoji, my addition) #NKFClinicals
Non-inferiority was not achieved with vadadustat but was achieved with daprodustat in non-dialysis patients #NKFClinicals
Onward to dialysis dependent. Once again the efficacy at raising the hemoglobin is clear and not in question….but MACE (major adverse cardiovascular events) is what we are interested in. #NKFClinicals
All three agents have demonstrated non-inferiority, but no signal for improved outcomes. #NKFClinicals
Interesting data looking at the + correlation between rate of Hgb rise and the risk of thromboembolic events. Hmmm. #NKFClinicals
HIF stabilizers may kill you but they sure improve the iron metabolism parameters #NKFClinicals
Summary slide #NKFClinicals
• • •
Missing some Tweet in this thread? You can try to
force a refresh
